Sign In

Aerocrine: 3.32m EUR in new funds

16 May 2001 10:54
By Tornado Staff

Aerocrine, a Stockholm biotechnology company that patented NIOX, a nitric monitoring product which is the cause of breathing inflammations like asthma, announced a capital increase with the flotation of 2.5 million new shares.

Old shareholders like Investor, the Wallenberg family finance company, and HealthCap Venture, a venture capital fund specialised in biotech companies are underwriting the flotation said to be worth 3.32 million euro along with the new investors 6AP Fonden and Health & Brands.

Related stories
Mucosis wins Wellcome Trust award and backing from current investors
Massive £50 million Series B round for UK-based Cell Medica
€6.3 million Series C for Humedics’ liver function diagnostic device
Medication safety system provider Mint Solutions secures €4.4 million
Big VC rounds for Ganymed and MISSION to fight cancer


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Aug 12€2.4MBusiness applications
Aug 12€0.7MMedical devices
Aug 12N/AMedical devices
Aug 9€7.0MSoftware development
Aug 9€0.3MeLearning
Aug 9N/AOther Biotechnology & Healthcare
Aug 7€3.8MDiagnostics

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.